Aurinia Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
AUPH$16.30-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years ended December 31, | |||
|---|---|---|---|
| (in thousands) | 2023 | 2022 | 2021 |
| Cash flows from operating activities: | |||
| Net loss | $(78,020) | $(108,180) | $(180,966) |
| Adjustments to reconcile consolidated net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 11,647 | 2,706 | 2,761 |
| Net amortization of premiums and discounts on investments | (12,141) | (1,572) | 660 |
| Upfront license and milestone expense | — | — | 10,000 |
| Share-based compensation | 45,311 | 32,300 | 31,243 |
| Write-down of inventory | 916 | 3,646 | 245 |
| Foreign exchange on finance lease liability | 5,949 | — | — |
| Other, net | (1,515) | (1,612) | (2) |
| Net changes in operating assets and liabilities: | |||
| Accounts receivable, net | (10,606) | 1,927 | (15,415) |
| Inventories, net | (15,869) | (9,072) | (5,644) |
| Prepaid expenses and other current assets | 4,399 | (2,404) | (5,335) |
| Non-current operating assets | (16) | (363) | 353 |
| Accounts payable, accrued and other liabilities | 13,394 | 699 | 4,076 |
| Deferred revenue | 3,763 | 3,048 | — |
| Operating lease liabilities | (673) | (652) | 332 |
| Net cash used in operating activities | (33,461) | (79,529) | (157,692) |
| Cash flows from investing activities: | |||
| Proceeds from investments | 529,376 | 464,316 | 354,427 |
| Purchase of investments | (523,500) | (523,993) | (438,958) |
| Upfront lease payment | (11,864) | (663) | (11,838) |
| Upfront license payment | — | — | (6,000) |
| Purchase of long-lived assets and intangibles | (718) | (292) | (303) |
| Additions to internal use-software implementation costs | — | — | (1,198) |
| Net cash used in investing activities | (6,706) | (60,632) | (103,870) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common shares pursuant to Public Offering, net of issuance costs | — | — | 196,740 |
| Proceeds from exercise of stock options, employee share purchase plan and warrants | 4,895 | 2,433 | 24,372 |
| Finance lease payments | (10,025) | — | — |
| Net cash (used in) provided by financing activities | (5,130) | 2,433 | 221,112 |
| Net decrease in cash and cash equivalents during the year | (45,297) | (137,728) | (40,450) |
| Cash and cash equivalents, beginning of the year | 94,172 | 231,900 | 272,350 |
| Cash, cash equivalents and restricted cash, end of the year | $48,875 | $94,172 | $231,900 |
| Supplemental cash flow information: | |||
| Cash paid for taxes | $(496) | $(1,979) | $(257) |
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets | |||
| Cash, cash equivalents | $48,755 | $94,088 | $231,643 |
| Restricted cash | 120 | 84 | 257 |
| Total cash, cash equivalents and restricted cash | $48,875 | $94,172 | $231,900 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.